Merck & Co. Inc.

Merck & Co. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. The company's segments are: Pharmaceutical, which includes human health pharmaceutical products that consist of therapeutic and preventive agents for the treatment of human disorders, and human health vaccine products that consist of preventive pediatric, adolescent and adult vaccines; and Animal Health, which discovers, develops, manufactures and markets veterinary pharmaceuticals, vaccines and health management solutions and services, as well as a suite of digitally connected identification, traceability and monitoring products.
  • TickerMRK
  • ISINUS58933Y1055
  • ExchangeNew York Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
MRK Merck & Co. Inc... (Health Care)

MERCK & COMPANY with less fundamental stars is reduced to Neutral

MERCK & COMPANY (US), a company active in the Pharmaceuticals industry, loses a star(s) at the fundamental level and sees its general evaluation downgraded. The independent financial analyst theScreener just removed a fundamental star(s) for a 2 over 4-star rating. As such, market behaviour remains unchanged and is evaluated as moderately risky. theScreener believes that the loss of a star(s) merits downgrade to the general evaluation of the title, which passes to Neutral. As of the analysis date July 23, 2021, the closing price was USD 77.54 and its expected value was estimated at USD 76.42.

MRK Merck & Co. Inc... (Health Care)

Merck & Co Inc: 1 director sold

A director at Merck & Co Inc sold 280,000 shares at 81.418USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

Valens Research
  • Valens Research
MRK Merck & Co. Inc... (Health Care)

MRK - Embedded Expectations Analysis - 2020 04 09

Merck & Co., Inc. (MRK:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with a 14.9x Uniform P/E. At these levels, the market has bearish expectations for the firm, and management appears concerned about KEYTRUDA, their spin-off, and revenue declines Specifically, management may be concerned about projected revenue declines, their strategic growth initiatives, and the potential of their spin-off to be dilutive. In addition, they may lack confidence in their ability to expand operating margins, capitalize on key growth drivers, and improve their operat...

Valens Research
  • Valens Research
MRK Merck & Co. Inc... (Health Care)

MRK - Embedded Expectations Analysis - 2020 02 20

 Merck & Co, Inc. (MRK:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 17.0x Uniform P/E. Even at these levels, the market has somewhat bullish expectations for the firm, but management appears concerned about KEYTRUDA, pricing pressures, and their innovative treatment portfolio  Specifically, management may be concerned about the launch of KEYTRUDA in combination with chemotherapy, their investments into pipeline opportunities, and increased pricing pressure among mature products, particularly in China. Moreover, they may lack confidence...

Damien Conover
  • Damien Conover
MRK Merck & Co. Inc... (Health Care)

Progress With Senate Drug Pricing Reform Fits Our Prior Analysis; No F...

Senate Finance Committee Chairman Chuck Grassley and Democratic ranking member Ron Wyden posted the Prescription Drug Pricing Reduction Act on Tuesday, and although this is not a final bill (it needs to proceed through markup on Thursday and get a majority vote of the full committee, so it could see changes before it proceeds to a Senate floor vote), it likely means that a bipartisan agreement was reached prior to posting. Share prices of drug firms were largely unmoved by this news; while we th...

MRK Merck & Co. Inc... (Health Care)

MERCK & COMPANY with less fundamental stars is reduced to Neutral

MERCK & COMPANY (US), a company active in the Pharmaceuticals industry, loses a star(s) at the fundamental level and sees its general evaluation downgraded. The independent financial analyst theScreener just removed a fundamental star(s) for a 2 over 4-star rating. As such, market behaviour remains unchanged and is evaluated as moderately risky. theScreener believes that the loss of a star(s) merits downgrade to the general evaluation of the title, which passes to Neutral. As of the analysis date July 23, 2021, the closing price was USD 77.54 and its expected value was estimated at USD 76.42.

MRK Merck & Co. Inc... (Health Care)

Merck & Co Inc: 1 director sold

A director at Merck & Co Inc sold 280,000 shares at 81.418USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

Valens Research
  • Valens Research
MRK Merck & Co. Inc... (Health Care)

MRK - Embedded Expectations Analysis - 2020 04 09

Merck & Co., Inc. (MRK:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with a 14.9x Uniform P/E. At these levels, the market has bearish expectations for the firm, and management appears concerned about KEYTRUDA, their spin-off, and revenue declines Specifically, management may be concerned about projected revenue declines, their strategic growth initiatives, and the potential of their spin-off to be dilutive. In addition, they may lack confidence in their ability to expand operating margins, capitalize on key growth drivers, and improve their operat...

Valens Research
  • Valens Research
MRK Merck & Co. Inc... (Health Care)

MRK - Embedded Expectations Analysis - 2020 02 20

 Merck & Co, Inc. (MRK:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 17.0x Uniform P/E. Even at these levels, the market has somewhat bullish expectations for the firm, but management appears concerned about KEYTRUDA, pricing pressures, and their innovative treatment portfolio  Specifically, management may be concerned about the launch of KEYTRUDA in combination with chemotherapy, their investments into pipeline opportunities, and increased pricing pressure among mature products, particularly in China. Moreover, they may lack confidence...

Damien Conover
  • Damien Conover
MRK Merck & Co. Inc... (Health Care)

Progress With Senate Drug Pricing Reform Fits Our Prior Analysis; No F...

Senate Finance Committee Chairman Chuck Grassley and Democratic ranking member Ron Wyden posted the Prescription Drug Pricing Reduction Act on Tuesday, and although this is not a final bill (it needs to proceed through markup on Thursday and get a majority vote of the full committee, so it could see changes before it proceeds to a Senate floor vote), it likely means that a bipartisan agreement was reached prior to posting. Share prices of drug firms were largely unmoved by this news; while we th...

MRK Merck & Co. Inc... (Health Care)

MERCK & COMPANY with less fundamental stars is reduced to Neutral

MERCK & COMPANY (US), a company active in the Pharmaceuticals industry, loses a star(s) at the fundamental level and sees its general evaluation downgraded. The independent financial analyst theScreener just removed a fundamental star(s) for a 2 over 4-star rating. As such, market behaviour remains unchanged and is evaluated as moderately risky. theScreener believes that the loss of a star(s) merits downgrade to the general evaluation of the title, which passes to Neutral. As of the analysis date July 23, 2021, the closing price was USD 77.54 and its expected value was estimated at USD 76.42.

MRK Merck & Co. Inc... (Health Care)

Merck & Co Inc: 1 director sold

A director at Merck & Co Inc sold 280,000 shares at 81.418USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

Valens Research
  • Valens Research
MRK Merck & Co. Inc... (Health Care)

MRK - Embedded Expectations Analysis - 2020 04 09

Merck & Co., Inc. (MRK:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with a 14.9x Uniform P/E. At these levels, the market has bearish expectations for the firm, and management appears concerned about KEYTRUDA, their spin-off, and revenue declines Specifically, management may be concerned about projected revenue declines, their strategic growth initiatives, and the potential of their spin-off to be dilutive. In addition, they may lack confidence in their ability to expand operating margins, capitalize on key growth drivers, and improve their operat...

Valens Research
  • Valens Research
MRK Merck & Co. Inc... (Health Care)

MRK - Embedded Expectations Analysis - 2020 02 20

 Merck & Co, Inc. (MRK:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 17.0x Uniform P/E. Even at these levels, the market has somewhat bullish expectations for the firm, but management appears concerned about KEYTRUDA, pricing pressures, and their innovative treatment portfolio  Specifically, management may be concerned about the launch of KEYTRUDA in combination with chemotherapy, their investments into pipeline opportunities, and increased pricing pressure among mature products, particularly in China. Moreover, they may lack confidence...

Damien Conover
  • Damien Conover
MRK Merck & Co. Inc... (Health Care)

Progress With Senate Drug Pricing Reform Fits Our Prior Analysis; No F...

Senate Finance Committee Chairman Chuck Grassley and Democratic ranking member Ron Wyden posted the Prescription Drug Pricing Reduction Act on Tuesday, and although this is not a final bill (it needs to proceed through markup on Thursday and get a majority vote of the full committee, so it could see changes before it proceeds to a Senate floor vote), it likely means that a bipartisan agreement was reached prior to posting. Share prices of drug firms were largely unmoved by this news; while we th...

MRK Merck & Co. Inc... (Health Care)

MERCK & COMPANY with less fundamental stars is reduced to Neutral

MERCK & COMPANY (US), a company active in the Pharmaceuticals industry, loses a star(s) at the fundamental level and sees its general evaluation downgraded. The independent financial analyst theScreener just removed a fundamental star(s) for a 2 over 4-star rating. As such, market behaviour remains unchanged and is evaluated as moderately risky. theScreener believes that the loss of a star(s) merits downgrade to the general evaluation of the title, which passes to Neutral. As of the analysis date July 23, 2021, the closing price was USD 77.54 and its expected value was estimated at USD 76.42.

MRK Merck & Co. Inc... (Health Care)

Merck & Co Inc: 1 director sold

A director at Merck & Co Inc sold 280,000 shares at 81.418USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

Valens Research
  • Valens Research
MRK Merck & Co. Inc... (Health Care)

MRK - Embedded Expectations Analysis - 2020 04 09

Merck & Co., Inc. (MRK:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with a 14.9x Uniform P/E. At these levels, the market has bearish expectations for the firm, and management appears concerned about KEYTRUDA, their spin-off, and revenue declines Specifically, management may be concerned about projected revenue declines, their strategic growth initiatives, and the potential of their spin-off to be dilutive. In addition, they may lack confidence in their ability to expand operating margins, capitalize on key growth drivers, and improve their operat...

Valens Research
  • Valens Research
MRK Merck & Co. Inc... (Health Care)

MRK - Embedded Expectations Analysis - 2020 02 20

 Merck & Co, Inc. (MRK:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 17.0x Uniform P/E. Even at these levels, the market has somewhat bullish expectations for the firm, but management appears concerned about KEYTRUDA, pricing pressures, and their innovative treatment portfolio  Specifically, management may be concerned about the launch of KEYTRUDA in combination with chemotherapy, their investments into pipeline opportunities, and increased pricing pressure among mature products, particularly in China. Moreover, they may lack confidence...

Damien Conover
  • Damien Conover
MRK Merck & Co. Inc... (Health Care)

Progress With Senate Drug Pricing Reform Fits Our Prior Analysis; No F...

Senate Finance Committee Chairman Chuck Grassley and Democratic ranking member Ron Wyden posted the Prescription Drug Pricing Reduction Act on Tuesday, and although this is not a final bill (it needs to proceed through markup on Thursday and get a majority vote of the full committee, so it could see changes before it proceeds to a Senate floor vote), it likely means that a bipartisan agreement was reached prior to posting. Share prices of drug firms were largely unmoved by this news; while we th...

MRK Merck & Co. Inc... (Health Care)

MERCK & COMPANY with less fundamental stars is reduced to Neutral

MERCK & COMPANY (US), a company active in the Pharmaceuticals industry, loses a star(s) at the fundamental level and sees its general evaluation downgraded. The independent financial analyst theScreener just removed a fundamental star(s) for a 2 over 4-star rating. As such, market behaviour remains unchanged and is evaluated as moderately risky. theScreener believes that the loss of a star(s) merits downgrade to the general evaluation of the title, which passes to Neutral. As of the analysis date July 23, 2021, the closing price was USD 77.54 and its expected value was estimated at USD 76.42.

MRK Merck & Co. Inc... (Health Care)

Merck & Co Inc: 1 director sold

A director at Merck & Co Inc sold 280,000 shares at 81.418USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

Valens Research
  • Valens Research
MRK Merck & Co. Inc... (Health Care)

MRK - Embedded Expectations Analysis - 2020 04 09

Merck & Co., Inc. (MRK:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with a 14.9x Uniform P/E. At these levels, the market has bearish expectations for the firm, and management appears concerned about KEYTRUDA, their spin-off, and revenue declines Specifically, management may be concerned about projected revenue declines, their strategic growth initiatives, and the potential of their spin-off to be dilutive. In addition, they may lack confidence in their ability to expand operating margins, capitalize on key growth drivers, and improve their operat...

Valens Research
  • Valens Research
MRK Merck & Co. Inc... (Health Care)

MRK - Embedded Expectations Analysis - 2020 02 20

 Merck & Co, Inc. (MRK:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 17.0x Uniform P/E. Even at these levels, the market has somewhat bullish expectations for the firm, but management appears concerned about KEYTRUDA, pricing pressures, and their innovative treatment portfolio  Specifically, management may be concerned about the launch of KEYTRUDA in combination with chemotherapy, their investments into pipeline opportunities, and increased pricing pressure among mature products, particularly in China. Moreover, they may lack confidence...

Damien Conover
  • Damien Conover
MRK Merck & Co. Inc... (Health Care)

Progress With Senate Drug Pricing Reform Fits Our Prior Analysis; No F...

Senate Finance Committee Chairman Chuck Grassley and Democratic ranking member Ron Wyden posted the Prescription Drug Pricing Reduction Act on Tuesday, and although this is not a final bill (it needs to proceed through markup on Thursday and get a majority vote of the full committee, so it could see changes before it proceeds to a Senate floor vote), it likely means that a bipartisan agreement was reached prior to posting. Share prices of drug firms were largely unmoved by this news; while we th...

MRK Merck & Co. Inc... (Health Care)

MERCK & COMPANY with less fundamental stars is reduced to Neutral

MERCK & COMPANY (US), a company active in the Pharmaceuticals industry, loses a star(s) at the fundamental level and sees its general evaluation downgraded. The independent financial analyst theScreener just removed a fundamental star(s) for a 2 over 4-star rating. As such, market behaviour remains unchanged and is evaluated as moderately risky. theScreener believes that the loss of a star(s) merits downgrade to the general evaluation of the title, which passes to Neutral. As of the analysis date July 23, 2021, the closing price was USD 77.54 and its expected value was estimated at USD 76.42.

MRK Merck & Co. Inc... (Health Care)

Merck & Co Inc: 1 director sold

A director at Merck & Co Inc sold 280,000 shares at 81.418USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

Valens Research
  • Valens Research
MRK Merck & Co. Inc... (Health Care)

MRK - Embedded Expectations Analysis - 2020 04 09

Merck & Co., Inc. (MRK:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with a 14.9x Uniform P/E. At these levels, the market has bearish expectations for the firm, and management appears concerned about KEYTRUDA, their spin-off, and revenue declines Specifically, management may be concerned about projected revenue declines, their strategic growth initiatives, and the potential of their spin-off to be dilutive. In addition, they may lack confidence in their ability to expand operating margins, capitalize on key growth drivers, and improve their operat...

Valens Research
  • Valens Research
MRK Merck & Co. Inc... (Health Care)

MRK - Embedded Expectations Analysis - 2020 02 20

 Merck & Co, Inc. (MRK:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 17.0x Uniform P/E. Even at these levels, the market has somewhat bullish expectations for the firm, but management appears concerned about KEYTRUDA, pricing pressures, and their innovative treatment portfolio  Specifically, management may be concerned about the launch of KEYTRUDA in combination with chemotherapy, their investments into pipeline opportunities, and increased pricing pressure among mature products, particularly in China. Moreover, they may lack confidence...

Damien Conover
  • Damien Conover
MRK Merck & Co. Inc... (Health Care)

Progress With Senate Drug Pricing Reform Fits Our Prior Analysis; No F...

Senate Finance Committee Chairman Chuck Grassley and Democratic ranking member Ron Wyden posted the Prescription Drug Pricing Reduction Act on Tuesday, and although this is not a final bill (it needs to proceed through markup on Thursday and get a majority vote of the full committee, so it could see changes before it proceeds to a Senate floor vote), it likely means that a bipartisan agreement was reached prior to posting. Share prices of drug firms were largely unmoved by this news; while we th...

MRK Merck & Co. Inc... (Health Care)

MERCK & COMPANY with less fundamental stars is reduced to Neutral

MERCK & COMPANY (US), a company active in the Pharmaceuticals industry, loses a star(s) at the fundamental level and sees its general evaluation downgraded. The independent financial analyst theScreener just removed a fundamental star(s) for a 2 over 4-star rating. As such, market behaviour remains unchanged and is evaluated as moderately risky. theScreener believes that the loss of a star(s) merits downgrade to the general evaluation of the title, which passes to Neutral. As of the analysis date July 23, 2021, the closing price was USD 77.54 and its expected value was estimated at USD 76.42.

MRK Merck & Co. Inc... (Health Care)

Merck & Co Inc: 1 director sold

A director at Merck & Co Inc sold 280,000 shares at 81.418USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

Valens Research
  • Valens Research
MRK Merck & Co. Inc... (Health Care)

MRK - Embedded Expectations Analysis - 2020 04 09

Merck & Co., Inc. (MRK:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with a 14.9x Uniform P/E. At these levels, the market has bearish expectations for the firm, and management appears concerned about KEYTRUDA, their spin-off, and revenue declines Specifically, management may be concerned about projected revenue declines, their strategic growth initiatives, and the potential of their spin-off to be dilutive. In addition, they may lack confidence in their ability to expand operating margins, capitalize on key growth drivers, and improve their operat...

Valens Research
  • Valens Research
MRK Merck & Co. Inc... (Health Care)

MRK - Embedded Expectations Analysis - 2020 02 20

 Merck & Co, Inc. (MRK:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 17.0x Uniform P/E. Even at these levels, the market has somewhat bullish expectations for the firm, but management appears concerned about KEYTRUDA, pricing pressures, and their innovative treatment portfolio  Specifically, management may be concerned about the launch of KEYTRUDA in combination with chemotherapy, their investments into pipeline opportunities, and increased pricing pressure among mature products, particularly in China. Moreover, they may lack confidence...

Damien Conover
  • Damien Conover
MRK Merck & Co. Inc... (Health Care)

Progress With Senate Drug Pricing Reform Fits Our Prior Analysis; No F...

Senate Finance Committee Chairman Chuck Grassley and Democratic ranking member Ron Wyden posted the Prescription Drug Pricing Reduction Act on Tuesday, and although this is not a final bill (it needs to proceed through markup on Thursday and get a majority vote of the full committee, so it could see changes before it proceeds to a Senate floor vote), it likely means that a bipartisan agreement was reached prior to posting. Share prices of drug firms were largely unmoved by this news; while we th...

MRK Merck & Co. Inc... (Health Care)

MERCK & COMPANY with less fundamental stars is reduced to Neutral

MERCK & COMPANY (US), a company active in the Pharmaceuticals industry, loses a star(s) at the fundamental level and sees its general evaluation downgraded. The independent financial analyst theScreener just removed a fundamental star(s) for a 2 over 4-star rating. As such, market behaviour remains unchanged and is evaluated as moderately risky. theScreener believes that the loss of a star(s) merits downgrade to the general evaluation of the title, which passes to Neutral. As of the analysis date July 23, 2021, the closing price was USD 77.54 and its expected value was estimated at USD 76.42.

MRK Merck & Co. Inc... (Health Care)

Merck & Co Inc: 1 director sold

A director at Merck & Co Inc sold 280,000 shares at 81.418USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

Valens Research
  • Valens Research
MRK Merck & Co. Inc... (Health Care)

MRK - Embedded Expectations Analysis - 2020 04 09

Merck & Co., Inc. (MRK:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with a 14.9x Uniform P/E. At these levels, the market has bearish expectations for the firm, and management appears concerned about KEYTRUDA, their spin-off, and revenue declines Specifically, management may be concerned about projected revenue declines, their strategic growth initiatives, and the potential of their spin-off to be dilutive. In addition, they may lack confidence in their ability to expand operating margins, capitalize on key growth drivers, and improve their operat...

Valens Research
  • Valens Research
MRK Merck & Co. Inc... (Health Care)

MRK - Embedded Expectations Analysis - 2020 02 20

 Merck & Co, Inc. (MRK:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 17.0x Uniform P/E. Even at these levels, the market has somewhat bullish expectations for the firm, but management appears concerned about KEYTRUDA, pricing pressures, and their innovative treatment portfolio  Specifically, management may be concerned about the launch of KEYTRUDA in combination with chemotherapy, their investments into pipeline opportunities, and increased pricing pressure among mature products, particularly in China. Moreover, they may lack confidence...

Damien Conover
  • Damien Conover
MRK Merck & Co. Inc... (Health Care)

Progress With Senate Drug Pricing Reform Fits Our Prior Analysis; No F...

Senate Finance Committee Chairman Chuck Grassley and Democratic ranking member Ron Wyden posted the Prescription Drug Pricing Reduction Act on Tuesday, and although this is not a final bill (it needs to proceed through markup on Thursday and get a majority vote of the full committee, so it could see changes before it proceeds to a Senate floor vote), it likely means that a bipartisan agreement was reached prior to posting. Share prices of drug firms were largely unmoved by this news; while we th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch